Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Organovo Holdings Stock Fell 5.2% In April

By Brian Feroldi - May 11, 2017 at 5:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of a transition in the corner office caused Organovo's shares to fall.

What happened

Investors in Organovo Holdings (ONVO -0.56%), a company focused on tissue engineering, had a rough April. The company's stock decline by 5.2% during the month, according to data from S&P Global Market Intelligence.

So what

It isn't hard to figure out why traders knocked down the company's share price. On April 11th, Organovo announced that its longtime CEO Keith Murphy would be stepping down as CEO "to pursue entrepreneurial opportunities". Organovo's Board of Directors hired Taylor Crouch to take his place. Taylor Crouch was the former CEO of a company called eStudySite and he has also held executive roles at companies such as Ligand Pharmaceuticals, Discovery Partners International, and Variagenics.

The changeout took place on April 24th.

man holding box of work stuff

Image Source: Getty Images.

Board member Dr. Kirk Malloy offered up the following commentary on the appointment of Taylor Crouch:

"Taylor is uniquely positioned to lead our growing company into its next phase given his significant commercial and operations experience.  We are confident that Taylor's extensive skills and expertise in the biotechnology and life sciences industries align with Organovo's strategy to capitalize fully on its growth opportunities.  The board looks forward to working with Taylor and the management team to execute against our strategy and continuing to create meaningful value for stockholders."

This news took the markets off-guard, which is why Organovo's stock declined in April.

Now what

Organovo's stock has been in a funk all year. Shares took a major step back in February after management cut its fiscal-year 2017 revenue guidance from a range of $4.5 million to $6.2 million to a range of $3.7 million to $4.5 million. The company stated that the shortfall was owed to the timing of some customer orders. Predictably, this news didn't sit well with growth investors.

While Organovo continues to boast exciting technology, there's little doubt that this company is in a tough position. The company ended 2016 with $70 million in cash but it lost $36.2 million last year. If current spending rates persist, then the company will be forced to raise capital sometime soon. That won't be easy given where the share price is today. When adding in the additional uncertainty that comes from a new CEO taking over, I, for one, continue to have no plans to buy this stock anytime soon.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Organovo Holdings, Inc. Stock Quote
Organovo Holdings, Inc.
ONVO
$1.76 (-0.56%) $0.01
Ligand Pharmaceuticals Incorporated Stock Quote
Ligand Pharmaceuticals Incorporated
LGND
$90.58 (1.52%) $1.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.